United States Health

Youlife (NASDAQ:YOUL) reported first-half 2026 revenue of RMB1,961.9 million, driven by its expanded workforce platform.

Eli Lilly (NYSE:LLY) reported that 27.7 percent of ulcerative colitis patients on Omvoh achieved corticosteroid-free disease control at one year.

Insmed (NASDAQ:INSM) initiated three Phase 3 studies in its PALM program, targeting total enrollment of over 2,000 patients.

Sarepta Therapeutics (NASDAQ:SRPT) presented new preclinical findings from its SRP-1003 program at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS).

Viking Therapeutics (NASDAQ:VKTX) announced the start of its SUNRISE Phase 3 clinical program for oral VK2735, an investigational therapy being developed for obesity management.

Parabilis Medicines (NASDAQ:PBLS) announced the initiation of a new dose-ranging cohort for zolucatetide in adults with familial adenomatous polyposis, a hereditary condition associated with the development of precancerous polyps.

Takeda Pharmaceutical (NYSE:TAK) presented new data from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating TAK-881 Immune Globulin Subcutaneous (Human), 20% Solution combined with recombinant human hyaluronidase.

Entrada Therapeutics (NASDAQ:TRDA) announced that an independent monitoring committee has recommended initiating Cohort 3 of its Phase 1/2 ELEVATE-44-201 clinical study.

Entrada Therapeutics (NASDAQ:TRDA) announced initial results from the first cohort of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45 in patients with Duchenne muscular dystrophy.

Eton Pharmaceuticals (NASDAQ:ETON) announced exclusive U.S. licensing and supply agreements with Aquestive Therapeutics (NASDAQ:AQST) for LIBERVANT, a seizure-cluster treatment.

Quoin Pharmaceuticals (NASDAQ:QNRX) announced that the European Medicines Agency has granted orphan drug designation to QRX003 for the treatment of Peeling Skin Syndrome, a rare genetic skin disorder.

Ocugen (NASDAQ:OCGN) entered an agreement granting Roots Pharmaceutical exclusive regional rights to OCU400, an investigational gene therapy for retinitis pigmentosa, an inherited vision-loss disease.